Demographics and characteristics of PSA, PSO and OA patients
| Baseline variables | PsA n=50 (48%) | PsO n=12 (11%) | Hand OA n=13 (12%) | |
| Socio-Demography /treatment | Females, n (%) | 21 (42) | 5 (41) | 13 (100) |
| Age, years, mean (SD) | 54.4 (12.0) | 55.3 (18.0) | 69.5 (8.9) | |
| Disease duration months | 60 (19;120) | 25 (12;96) | 78 (12;99) | |
| Height, cm, mean (SD) | 172.8 (10.0) | 173.3 (10.0) | 160.2 (6.7) | |
| weight, kg, mean (SD) | 85.7 (16.8) | 82.6 (16.3) | 62.7 (10.7) | |
| BMI m/kg2, mean (SD) | 28.8 (6.6) | 27.5 (5.3) | 24.3 (2.5) | |
| Treated with csDMARDS, n (%) | 30 (60) | 3 (25) | 1 (7)* | |
| Treated with bDMARDS, n (%) | 4 (8) | 5 (42) | 0 | |
| Treated with both bDMARDS and csDMARDS, n (%) | 7 (14) | 0 | 0 | |
| No treatment, n (%) | 9 (18) | 4 (33) | 12 (93) | |
| PROM | HAQ-DI (0–3) | 0.44 (0.13;0.88) | 0.00 (0.00;0.13) | 0.63 (0.25;0.88) |
| VAS Fatigue (0–100), mean (SD) | 47.6 (27.8) | 27.3 (22.9) | 24.8 (22.1) | |
| VAS Pain (0–100), mean (SD) | 36.2 (26.3) | 9.5 (10.8) | 42.2 (21.2) | |
| VAS Global (0–100), mean (SD) | 44.5 (28.0) | 14.6 (17.5) | 40.7 (22.9) | |
| Clinical measures | Swollen joint count (0–66) | 3.5 (1.0;5.0) | 1.0 (0;3.0) | 2.0 (1,0;4.0) |
| Tender joint count (0–68) | 6.5 (1.0;14.0) | 0.0 (0.0;2.0) | 9.0 (5.0;11.0) | |
| PASI (0–72) | 1.9 (0.8;4.0) | 1.8 (0.0;6,1) | 0.0 (0.0;0.0) | |
| SPARCC (0–16) | 2.0 (1.0;5.0) | 1.0 (0.0;2.0) | 2.0 (0.0;2.0) | |
| NAPSI-score total finger 2 (0–8) | 3.0 (2.0;4.0) | 3.5 (2.0;5.0) | 0.0 (0.0;0.0) | |
| NAPSI-score total finger 3 (0–8) | 3.0 (2.0;4.0) | 4.0 (2.3;4.8) | 0.0 (0.0;0.0) | |
| NAPSI-score total finger 4 (0–8) | 2.0 (1.0;4.0) | 3.5 (2.0;5.8) | 0.0 (0.0;0.0) | |
| NAPSI-score total finger 5 (0–8) | 2.0 (1.0;4.0) | 2.0 (1.0;3.0) | 0.0 (0.0;0.0) |
Data are presented as median (25th–75th percentiles) unless otherwise stated.
*One patient referred as PsA did not fulfil the CASPAR criteria at the screening visit and was thus rediagnosed as hand OA and had DMARD terminated upon inclusion.
bDMARD, biological DMARD; BMI, body mass index; csDMARD, conventional synthetic DMARD; DMARD, disease modifying antirheumatic drug; HAQ-DI, Health Assessment Questionnaire Disability Index; NAPSI, Nail Psoriasis Severity Index; OA, osteoarthritis; PASI, Psoriatic Area Severity Index; PROM, patient-reported outcome measures; PsA, psoriatic arthritis; PSO, psoriasis; SPARCC, Spondyloarthritis Research Consortium of Canada; VAS, Visual Analogue Scale.